A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Principal Investigator

Alex Gifford

Study Number

F19067

Summary

The purpose of this study is to evaluate the efficacy, safety, pharmacodynamic (PD) and pharmacokinetic (PK) effect of VX-561.

Phase

N/A

Contact

Dana Dorman

Available at the following location(s)

• Manchester

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms